VEMLIDY (Gilead Sciences, Inc.)
Welcome to the PulseAid listing for the VEMLIDY drug offered from Gilead Sciences, Inc.. This Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC],Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC],Nucleoside Analog [Chemical/Ingredient],Nucleoside Reverse Transcriptase Inhibitors [MoA] pharmaceutical is classified as a HUMAN PRESCRIPTION DRUG. Below, you can view details for this drug, such as its dosage form, route of delivery, start market/end market dates, and more. We have also randomly listed additional pharmaceuticals used in the same HUMAN PRESCRIPTION DRUG drug type category.
| LABELER NAME / MANUFACTURER: | Gilead Sciences, Inc. |
| NON-PROPRIETARY NAME: | tenofovir alafenamide |
| SUBSTANCE NAME: | TENOFOVIR ALAFENAMIDE FUMARATE |
| TYPE: | HUMAN PRESCRIPTION DRUG |
| PHARMA CLASS: | Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC],Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC],Nucleoside Analog [Chemical/Ingredient],Nucleoside Reverse Transcriptase Inhibitors [MoA] |
| ROUTE: | ORAL |
| DOSAGE FORM: | TABLET |
| MARKETING CATEGORY NAME: | NDA |
| START MARKETING DATE: | 2016-11-10 |
| END MARKETING DATE: | 0000-00-00 |
VEMLIDY HUMAN PRESCRIPTION DRUG Details:
| Item Description | VEMLIDY from Gilead Sciences, Inc. |
| LABELER NAME: | Gilead Sciences, Inc. |
| DEA SCHEDULE: |
|
| ACTIVE STRENGTH: | 25(mg/1) |
| START MARKETING DATE: | 2016-11-10 |
| END MARKETING DATE: | 0000-00-00 |
| PRODUCT ID: | 61958-2301_5ad06485-fa8d-4233-e053-2a91aa0a0575 |
| PRODUCT NDC: | 61958-2301 |
| APPLICATION NUMBER: | NDA208464 |
Other TENOFOVIR ALAFENAMIDE FUMARATE Pharmaceutical Manufacturers / Labelers:
